ClinicalTrials.gg
Active, not recruitingNCT05795244Updated Nov 18, 2026

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

A Phase 2 interventional study of Nivolumab in Endometrial Neoplasms and Endometrial Cancer, sponsored by Yonsei University. Active, not recruiting at 6 sites in South Korea. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Yonsei University · Phase 2, Interventional, and Treatment

How we know · 5 judgments · one reading being read again

Updated Nov 18, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Endometrial Neoplasms with a site in Korea, Republic of — 34 open to participants now, 59 under way, 17 of them phase 3. Endometrial Neoplasms · Korea, Republic of.

Enrollment
74th of 76
30 · median 287
Started
2023
with 6 others
Phase 2
19 of 85
7 open now
Primary completion
2026-02
later than 8 of 58 live
Registered
55th of 85
by date
Lead sponsor
4 of 85
Yonsei University

Among the 85 studies in Endometrial Neoplasms with a site in Korea, Republic of, this one is the 74th largest by enrollment of the 76 interventional ones that give a count, is one of 7 that started in 2023, is one of 19 in phase 2, reaches primary completion later than 8 of the 58 other live ones, and was the 55th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

34 of the 85 studies in Endometrial Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Endometrial Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

phase 2 clinical trial to confirm the pathological complete response rate of PD-1 blocker use in patients with Mismatch Repair Deficiency(MMRd) endometrial cancer that can be completely resected surgically.

Read the detailed description

Multi-center, non-randomized, open-label, A Phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer. A total of 30 subjects from 7 institutions in Korea will be enrolled in this trial.

Patients will be administered Nivolumab 480mg intravenously every 4 weeks for a total 6 cycles. After the 6 cycles of anti-cancer therapy, surgical resection will be performed. If clinical and pathological complete response is confirmed, it is possible to observe the patient's progress without surgical treatment.

03

Conditions studied

  • Endometrial Neoplasms
  • Endometrial Cancer
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

[Inclusion Criteria]

  1. Explicit and voluntary consent to participation in the trial obtained by signing and dating an form that clearly and completely describes the purpose, potential risks, and other important issues related to the study.
  2. Sex: female
  3. Age (at the time of informed consent): 20 years and older
  4. Subjects with -or cytologically-confirmed endometrial cancer or carcinosarcoma(Mixed Mullerain Tumor)
  5. Clinical stage: Stage I - IIIC2 and surgically completely resectable
  6. No evidence of distant
  7. MMRd or MSI-H subtype (defined by either deficient/loss expression of mismatch repair (MMR) proteins MLH1, PMS2, MSH2, MSH6 or microsatellite instability-high (MSI-H) by polymerase chain reaction assay for 5 microsatellite markers)
  8. Performance Status Score 0 or 1
  9. Patients with a of at least 3 months
  10. Patients whose latest laboratory data meet the below criteria within 7 days before first dose. If the date of the laboratory tests at the time of enrollment is not within 7 days before the first dose of the product, testing must be repeated within 7 days before the first dose of the investigational product, and these latest laboratory tests must meet the following criteria. Of note, laboratory data will not be valid if the patient has received a granulocyte colony-stimulating factor (G-CSF) or blood transfusion within 14 days before testing.

    • White blood cells ≥2,000/mm3 and neutrophils ≥1,500/mm3
    • ≥100,000/mm3 Protocol_Nivolumab_version 4.1_20250818 Page 15 / 39
    • ≥9.0 g/dL
    • (GOT) and ALT (GPT) ≤3.0-fold the (ULN) of the study site (or ≤5.0-fold the ULN of the study site in patients with liver metastases)
    • Total ≤1.5-fold the ULN of the study site
    • Creatinine ≤1.5-fold the ULN of the study site or (either the measured or estimated value using the Cockcroft-Gault equation) >45 mL/min
  11. Women of (including women with chemical menopause or no menstruation for other medical reasons)#1 must agree to use #2 from the time of informed consent until 5 months or more after the last dose of the investigational product. Also, women must agree not to breastfeed from the time of informed consent until 5 months or more after the last dose of the investigational product.

    • 1. Women of childbearing potential are defined as all women after the onset of menstruation who are not and have not been surgically sterilized (e.g., hysterectomy, bilateral tubal ligation, bilateral oophorectomy). Post-menopause is defined as amenorrhea for ≥12 consecutive months without specific reasons. Women using oral contraceptives, intrauterine devices, or mechanical contraception such as contraceptive barriers are regarded as having childbearing potential.
    • 2. The subject must consent to use any one of the following methods of contraception: a condom for the subject's partner (male), an intrauterine device (IUD) for female subjects, or skin implantation of a rod contraceptive (Implanon).
    • 3. Complete sexual abstinence is also acceptable: Sexual abstinence is considered highly effective only if it is defined as abstaining from sexual intercourse with the opposite sex for the entire duration of the trial treatment-related risks. The reliability of sexual abstinence in relation to the duration of the trial needs to be evaluated, and sexual abstinence should be a preferred and routine lifestyle of the subjects.

[Exclusion Criteria]

  1. Patients with multiple primary cancers (except for cancer that are not expected to affect the clinical trial outcomes, such as completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer, or any other cancer that has not recurred for at least 3 years). Other exceptions may apply and discussion between the investigator and the sponsor may be necessary.
  2. Patients with residual adverse effects of prior therapy or effects of surgery that would affect the safety evaluation of the investigational product in the opinion of the investigator or sub-investigator.
  3. Patients with current or past history of severe to any other antibody products
  4. Patients with concurrent disease or history of chronic or recurrent autoimmune disease
  5. Patients with a current or past history of interstitial lung disease or pulmonary fibrosis diagnosed based on imaging or clinical findings. Patients with radiation pneumonitis may be randomized if the radiation pneumonitis has been confirmed as stable (beyond acute phase) without any concerns about recurrence.
  6. Patients with concurrent diverticulitis or symptomatic gastrointestinal ulcerative disease
  7. Patients with pericardial fluid, pleural effusion, or ascites requiring treatment
  8. Patients with uncontrollable, tumor-related pain Protocol_Nivolumab_version 4.1_20250818 Page 16 / 39
  9. Patients who have experienced a , cerebrovascular accident, thrombosis, or thromboembolism (pulmonary arterial embolism or deep vein thrombosis) within 180 days before randomization
  10. Patients with a history of uncontrollable or significant cardiovascular disease meeting any of the following criteria:

    • Myocardial infarction within 180 days before randomization
    • Uncontrollable angina pectoris within 180 days before randomization
    • (NYHA) Class III or IV congestive heart failure
    • Uncontrollable hypertension despite appropriate treatment (e.g., systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥ 90 mmHg lasting 24 hours or more)
    • Arrhythmia requiring treatment
  11. Patients receiving or requiring anticoagulant therapy for a disease. Patients receiving antiplatelet therapy including low-dose aspirin may be enrolled.
  12. Patients with uncontrollable diabetes mellitus
  13. Patients with systemic infections requiring treatment
  14. Patients who have received systemic (except for temporary use, e.g., for examination or prophylaxis of allergic reactions) or within 28 days before randomization
  15. Patients who have received antineoplastic drugs (e.g., chemotherapy agents, molecular-targeted therapy agents, or immunotherapy agents) within 28 days before randomization
  16. Patients who have undergone surgical adhesion of the pleura or pericardium within 28 days before randomization
  17. Patients who underwent major surgery within 4 weeks or minor surgery within 7 days prior to administration of the first investigational drug. Subjects should have adequately recovered from toxicity or complications from the intervention prior to initiation of study drug administration. Subjects planning major surgery during the treatment period should be excluded from the study (however, 2 weeks for video-assisted thoracoscopic surgery (VATS) or open-and-closed (ONC) surgery).

    Note) Dilation and curettage under general anesthesia for diagnostic purposes is not applicable to the above, and the subject can be enrolled when the investigator judged that the patient has adequately recovered from the complications caused by the intervention.

  18. Patients who have received radiotherapy within 28 days before randomization, or radiotherapy to bone metastases within 14 days before randomization
  19. Patients who have received any radiopharmaceuticals (except for examination or diagnostic use of radiopharmaceuticals) within 56 days before randomization
  20. Patients with a positive test result for any of the following: -1 antibody, HIV-2 antibody, HBs antigen, or antibody. Subjects who are positive can participate in the study if their HBV-DNA level is below the institutional lower limit of detection.
  21. Women who are pregnant or breastfeeding, or possibly pregnant
  22. Patients who have received any other unapproved drug (e.g., investigational use of drugs, unapproved combined formulations, or unapproved dosage forms) within 28 days before randomization
  23. Patients who have previously received Nivolumab, antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, anti-CTLA-4 antibody or other therapeutic antibodies or pharmacotherapies for regulation of T-cells
  24. Patients judged to be incapable of providing consent for reasons such as concurrent dementia
  25. Other patients judged by the investigator or sub-investigator to be inappropriate as subjects of this study
  26. Patient with current or past history of hypersensitivity to Nivolumab.
  27. WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Experimental

    Drug: Nivolumab

Interventions

  • \- Nivolumab 480 mg/every 4 weeks/IV infusion/6 cycles

    Also known as: Opdivo

06

What researchers measure

Primary outcomes

  1. pathologic complete response

    Tumor response evaluation will be conducted based on imaging tests and pathological response of the endometrium. The evaluation of endometrium should be performed using Dilatation \& Currettage or hysteroscopic biopsy every 3 cycles.

    Time frame: At 6 months

Secondary outcomes

  1. Objective response rate (ORR)

    Objective response rate is defined according to RECIST v1.1 or iRECIST.

    Time frame: At 6 months

  2. Progression free survival (PFS)

    PFS is defined as the time from treatment start until the first documented sign of disease progression or death from any cause.

    Time frame: From the first dose of nivolumab until disease progression or initiation of subsequent anticancer therapy, whichever occurs first, assessed up to 3 years.

  3. Overall survival (OS)

    OS is defined as the time from first treatment until death from any cause.

    Time frame: Approximately up to 6 years.

  4. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    The number and proportion of participants experiencing treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), will be assessed. TEAEs are defined as adverse events that occur after the first dose of nivolumab or pre-existing adverse events that worsen following treatment exposure. Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

    Time frame: From the first dose of nivolumab through 90 days after the last dose of nivolumab (approximately 9 months).

07

Study locations

6 sites
08

References and documents

Publications

  • Lee YJ, Lee YY, Park JY, Cho HW, Lim MC, Kim MK, Lee JM, Lee JY. A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC). J Gynecol Oncol. 2025 May;36(3):e35. doi: 10.3802/jgo.2025.36.e35. Epub 2024 Oct 23. PubMed 39530558 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Feb 2026, 27 months.

Of 109 non-industry phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 115. This study's 27 months is below that.

Counting every sponsor, half of 141 studies reached it within 55 months; a quarter within 37 and three quarters within 115.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2029 → Feb 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2023
First posted
Apr 3, 2023
StartActual
Oct 31, 2023
Primary completionActual
Feb 24, 2026was Dec 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 18, 2026
Sites
5 sites added
Show 5 added (5 South Korea)
  • National Cancer Center · Goyang-si, South Korea
  • Kyung Hee University Hospital at Gangdong · Seoul, South Korea
  • Asan Medical Center · Seoul, South Korea
  • Samsung Medical Center · Seoul, South Korea
  • Korea University Guro Hospital · Seoul, South Korea
Nov 18, 2026
Primary completion
Dec 2029→Feb 24, 2026 (actual)
Nov 18, 2026
Eligibility
3 exclusion criteria removed; 10 criteria edited, 4 added
What changed in the criteria
  • Added[Inclusion Criteria]
  • EditedExplicit and voluntary consent to participation in the trial obtained by signing and dating aan informed consent form that clearly and completely describes the purpose, potential risks, and other important issues related to the trialstudy.
  • EditedSubjects with histologically-or cytologically-confirmed endometrial cancer or carcinosarcoma(Mixed MullerianMullerain Tumor)
  • EditedPatients whose latest laboratory data meet the below criteria within 7 days before first dose. If the date of the laboratory tests at the time of enrollment is not within 7 days before the first dose of the investigational product, testing must be repeated within 7 days before the first dose of the investigational product, and these latest laboratory tests must meet the following criteria. Of note, laboratory data will not be valid if the patient has received a granulocyte colony-stimulating factor (G -CSF) or blood transfusion within 14 days before testing.
  • EditedPlatelets ≥100,000/mm3 Protocol_Nivolumab_version 4.1_20250818 Page 15 / 39
  • EditedWomen of childbearing potential (including women with chemical menopause or no menstruation for other medical reasons)#1 must agree to use contraception#2 from the time of informed consent until 5months5 months or more after the last dose of the investigational product. Also, women must agree not to breastfeed from the time of informed consent until 5 months or more after the last dose of the investigational product.
  • Added[Exclusion Criteria]
  • EditedPatients with multiple primary cancers (withexcept for cancer that are not expected to affect the exception ofclinical trial outcomes, such as completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer, or any other cancer that has not recurred for at least 53 years). Other exceptions may apply and discussion between the investigator and the sponsor may be necessary.
  • EditedPatients with uncontrollable, tumor-related pain Protocol_Nivolumab_version 4.1_20250818 Page 16 / 39
  • EditedUncontrollable hypertension despite appropriate treatment (e.g., systolic blood pressure ≥150mmHg150 mmHg or diastolic blood pressure ≥ 90 mmHg lasting 24 hours or more)
  • AddedPatients who underwent major surgery within 4 weeks or minor surgery within 7 days prior to administration of the first investigational drug. Subjects should have adequately recovered from toxicity or complications from the intervention prior to initiation of study drug administration. Subjects planning major surgery during the treatment period should be excluded from the study (however, 2 weeks for video-assisted thoracoscopic surgery (VATS) or open-and-closed (ONC) surgery).
  • AddedNote) Dilation and curettage under general anesthesia for diagnostic purposes is not applicable to the above, and the subject can be enrolled when the investigator judged that the patient has adequately recovered from the complications caused by the intervention.
  • EditedPatients with a positive test result for any of the following: HIV-1 antibody, HIV-2 antibody, HTLV-1 antibody, HBs antigen, or HCV antibody. Subjects who are HBsAg positive can participate in the study if their HBV-DNA level is below the institutional lower limit of detection.
  • EditedPatients who have previously received Nivolumab, anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD -L2 antibody, anti-CD137 antibody, anti-CTLA-4 antibody or other therapeutic antibodies or pharmacotherapies for regulation of T-cells
Exclusion criteria
  • RemovedPatients who have undergone surgery under general anesthesia within 28 days before randomization
  • RemovedPatients who have undergone surgery involving local or topical anesthesia within 14 days before randomization
  • RemovedPatients with a negative HBs antigen test but a positive test result for either HBs antibody or HBc antibody with a detectable level of HBV-DNA
Nov 18, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time framepathologic complete responseAt 3 months → At 6 months
Nov 18, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 39530558 ↗
Nov 18, 2026
Secondary outcomes
2 time frame changed, 1 added
What changed in the outcomes
  • AddedIncidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: From the first dose of nivolumab through 90 days after the last dose of nivolumab (approximately 9 months).
  • Time frameObjective response rate (ORR)At 3 months → At 6 months
  • Time frameProgression free survival (PFS)1 year → From the first dose of nivolumab until disease progression or initiation of subsequent anticancer therapy, whichever occurs first, assessed up to 3 years.
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Active, not recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 39530558 ↗
    5 sites added
    Show 5 added (5 South Korea)
    • National Cancer Center · Goyang-si, South Korea
    • Kyung Hee University Hospital at Gangdong · Seoul, South Korea
    • Asan Medical Center · Seoul, South Korea
    • Samsung Medical Center · Seoul, South Korea
    • Korea University Guro Hospital · Seoul, South Korea
    Primary completion Dec 2029→Feb 24, 2026 (now actual)
    Eligibility 3 exclusion criteria removed; 10 criteria edited, 4 added
    What changed in the criteria
    • Added[Inclusion Criteria]
    • EditedExplicit and voluntary consent to participation in the trial obtained by signing and dating aan informed consent form that clearly and completely describes the purpose, potential risks, and other important issues related to the trialstudy.
    • EditedSubjects with histologically-or cytologically-confirmed endometrial cancer or carcinosarcoma(Mixed MullerianMullerain Tumor)
    • EditedPatients whose latest laboratory data meet the below criteria within 7 days before first dose. If the date of the laboratory tests at the time of enrollment is not within 7 days before the first dose of the investigational product, testing must be repeated within 7 days before the first dose of the investigational product, and these latest laboratory tests must meet the following criteria. Of note, laboratory data will not be valid if the patient has received a granulocyte colony-stimulating factor (G -CSF) or blood transfusion within 14 days before testing.
    • EditedPlatelets ≥100,000/mm3 Protocol_Nivolumab_version 4.1_20250818 Page 15 / 39
    • EditedWomen of childbearing potential (including women with chemical menopause or no menstruation for other medical reasons)#1 must agree to use contraception#2 from the time of informed consent until 5months5 months or more after the last dose of the investigational product. Also, women must agree not to breastfeed from the time of informed consent until 5 months or more after the last dose of the investigational product.
    • Added[Exclusion Criteria]
    • EditedPatients with multiple primary cancers (withexcept for cancer that are not expected to affect the exception ofclinical trial outcomes, such as completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer, or any other cancer that has not recurred for at least 53 years). Other exceptions may apply and discussion between the investigator and the sponsor may be necessary.
    • EditedPatients with uncontrollable, tumor-related pain Protocol_Nivolumab_version 4.1_20250818 Page 16 / 39
    • EditedUncontrollable hypertension despite appropriate treatment (e.g., systolic blood pressure ≥150mmHg150 mmHg or diastolic blood pressure ≥ 90 mmHg lasting 24 hours or more)
    • AddedPatients who underwent major surgery within 4 weeks or minor surgery within 7 days prior to administration of the first investigational drug. Subjects should have adequately recovered from toxicity or complications from the intervention prior to initiation of study drug administration. Subjects planning major surgery during the treatment period should be excluded from the study (however, 2 weeks for video-assisted thoracoscopic surgery (VATS) or open-and-closed (ONC) surgery).
    • AddedNote) Dilation and curettage under general anesthesia for diagnostic purposes is not applicable to the above, and the subject can be enrolled when the investigator judged that the patient has adequately recovered from the complications caused by the intervention.
    • EditedPatients with a positive test result for any of the following: HIV-1 antibody, HIV-2 antibody, HTLV-1 antibody, HBs antigen, or HCV antibody. Subjects who are HBsAg positive can participate in the study if their HBV-DNA level is below the institutional lower limit of detection.
    • EditedPatients who have previously received Nivolumab, anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD -L2 antibody, anti-CD137 antibody, anti-CTLA-4 antibody or other therapeutic antibodies or pharmacotherapies for regulation of T-cells
    Exclusion criteria
    • RemovedPatients who have undergone surgery under general anesthesia within 28 days before randomization
    • RemovedPatients who have undergone surgery involving local or topical anesthesia within 14 days before randomization
    • RemovedPatients with a negative HBs antigen test but a positive test result for either HBs antibody or HBc antibody with a detectable level of HBV-DNA
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time framepathologic complete responseAt 3 months → At 6 months
    Secondary outcomes 2 time frame changed, 1 added
    What changed in the outcomes
    • AddedIncidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: From the first dose of nivolumab through 90 days after the last dose of nivolumab (approximately 9 months).
    • Time frameObjective response rate (ORR)At 3 months → At 6 months
    • Time frameProgression free survival (PFS)1 year → From the first dose of nivolumab until disease progression or initiation of subsequent anticancer therapy, whichever occurs first, assessed up to 3 years.
    + 5 other changes: verification date, responsible party, oversight details, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05795244
Lead sponsor
Yonsei University
Responsible party
JUNGYUN LEE (Principal Investigator, Yonsei University) — Principal investigator
First posted
Apr 3, 2023
Start date
Oct 31, 2023
Primary completion
Feb 24, 2026
Completion
Dec 31, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

JUNGYUN LEE
principal investigator · Severance Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion